INTRODUCTION
============

Programmable nuclease-based genome manipulation techniques have been extensively studied and improved ([@b1-molce-41-10-917]; [@b2-molce-41-10-917]; [@b3-molce-41-10-917]). These techniques are critical tools for biomedical research and may lead to management of many human genetic diseases by genome cleavage and/or editing. Early genome-editing efforts exploited endogenous homologous recombination, zinc-finger nucleases (ZFNs) and transcription-activator-like effector nucleases (TALENs) ([@b2-molce-41-10-917]; [@b3-molce-41-10-917]; [@b4-molce-41-10-917]; [@b25-molce-41-10-917]; [@b26-molce-41-10-917]). Although significant progress has been made by developing new programmable nucleases, many challenges remain, including improving the efficiency of genome editing and reducing off-target effects ([@b5-molce-41-10-917]; [@b15-molce-41-10-917]; [@b27-molce-41-10-917]).

These challenges have been partly overcome by new genome editing technologies based on the RNA-guided DNA endonuclease of the CRISPR/Cas system ([@b6-molce-41-10-917]; [@b11-molce-41-10-917]; [@b12-molce-41-10-917]; [@b16-molce-41-10-917]; [@b22-molce-41-10-917]; [@b28-molce-41-10-917]). CRISPR/Cas was originally discovered as part of a bacterial "immune system" ([@b11-molce-41-10-917]; [@b12-molce-41-10-917]; [@b16-molce-41-10-917]). The endonuclease activity of Cas protein complexed with a "guide RNA" produces double-stranded break (DSB) between certain bases in a target genomic DNA sequence complementary to the guide RNA ([@b10-molce-41-10-917]; [@b13-molce-41-10-917]). A genomic DNA sequence targeted by Cas should contain both a DNA sequence ("protospacer") that will base-pair with the guide RNA, and a short DNA sequence called the "protospacer-adjacent motif (PAM)" ([@b9-molce-41-10-917]; [@b11-molce-41-10-917]). Many Cas proteins have been identified or engineered and each requires a specific PAM ([@b21-molce-41-10-917]). RNA-guided DNA cleavage can lead to either non-homologous end joining (NHEJ)-induced random insertions and deletions (indels), or DNA replacement via homology-directed repair (HDR) in the presence of donor DNA. Mutated or engineered Cas proteins have been developed to reduce the off-target activity of Cas ([@b20-molce-41-10-917]; [@b29-molce-41-10-917]).

*TNFSF9* encodes the CD137 ligand (CD137L, also known as 4-1BBL). It is a member of the TNF family and is generally expressed on antigen-presenting cells and tumor cells ([@b32-molce-41-10-917]). CD137L binds to CD137, a TNFR family member, on T lymphocytes, and produces CD137 signals-mediated costimulatory responses in T cells ([@b23-molce-41-10-917]). Binding of CD137L by CD137 also elicits reverse signal transduction pathways and modulates innate immune responses ([@b18-molce-41-10-917]; [@b30-molce-41-10-917]). Recently we reported that CD137L reverse signals interact with lipopolysaccharide (LPS)-induced Toll-like receptor 4 (TLR4) responses in myeloid cells in complexes of CD137L/TMEM126A/TLR4 ([@b19-molce-41-10-917]).

In this study, with the aim of examining the real-time localization of endogenous CD137L, we used CRISPR-Cas9-mediated gene editing in HepG2 cells to mutate two nucleotides of T[CT]{.ul} encoding the 172^th^ amino acid (Ser) of human CD137L in *TNFSF9* to T[AG]{.ul}, which is transcribed into an amber stop codon. The TAG in *TNFSF9* can function as a codon for the fluorescent unnatural amino acid, L-Anap in the presence of Anap-specific tRNA~CUA~/AnapRS ([@b24-molce-41-10-917]; [@b31-molce-41-10-917]). Our aim was to visualize L-Anap-incorporated endogenous CD137L in living cells by fluorescence microscopy.

Although the CRISPR-Cas9 technique produced the 2-base-edited T[AG]{.ul} sequence in genomic *TNFSF9*, we found that the cDNA derived from it instead contained the wild-type triplet T[CT]{.ul}, indicating that transcripts of the TAG sequence contained the codon [AG]{.ul}A instead of [CU]{.ul}A. This is the first report of re-editing (correcting) of transcripts follows programmable nuclease-mediated gene editing.

MATERIALS AND METHODS
=====================

Cell culture
------------

Cells of the human hepatocyte carcinoma HepG2 cell line were cultured in αMEM/10% FBS in the presence of penicillin and streptomycin. Confluent cells were detached with trypsin/EDTA solution and diluted fourfold in fresh medium. For cryopreservation, 5 × 10^5^ cells per vial were resuspended in 1ml CellBanker (AMS Biotech., UK) and stored at −70°C. Mutant HepG2 clones 9-1, 14 and 5 were cultured along with wild type cells with continuous sub-culture for more than one year.

Editing *TNFSF9* with CRISPR-Cas9
---------------------------------

Point mutations of human *TNFSF9* (19q13.3) were generated in Hep G2 cells as follows: first, programmable endonuclease activity of CRISPR-Cas9 was confirmed using T7 endonuclease 1 assays after transfecting the vectors for the guide RNA (pRGEN_U6_sgRNA) and Cas9 (pRGEN_Cas9\_ CMV) into 293 T cells. sgRNAs containing PAM sequences were designed to target the nucleotides encoding Ser^172^ (ToolGen, Korea). After identifying a suitable sgRNA by confirming cleavage of the target sequence, pRGEN_U6_sgRNA and pRGEN_Cas9_CMV were cotransfected into Hep G2 cells along with a reporter plasmid and a double-stranded donor DNA containing the proto spacer region with right and left arms to mutate the second and third bases of T[CT]{.ul} to TAG. The sequence of ds donor DNA was as follows: 5′gctcaggctccgtttcacttgcgctgcacctgcagccactgcgctAGgctgctg gggccgccgccctggctttgaccgtggacc-3′ (uppercase underlining indicates the mutation of Ser 172 to a stop codon). The RGEN target region (the 23mer proto spacer region) is in bold, and the left and right arms, are in lower case. The transfected cells were plated to form individual clones and clones with the desired triplet change were identified by isolating genomic DNA from random clones followed by PCR for *TNFSF9* and DNA sequencing.

Isolation of genomic DNA and PCR amplification of genomic *TNFSF9*
------------------------------------------------------------------

Genomic DNA was isolated from HepG2 cells with a PureLink^™^ Genomic DNA Mini Kit (Invitrogen, USA) following the instruction manual. PCR was performed with Blend Taq polymerase (TOYOBO, Japan). PCR conditions and primers for amplification of *TNFSF9* and the sgRNA plasmid are given in [Table 1](#t1-molce-41-10-917){ref-type="table"}. PCR products were separated by running on 1.2% agarose gels. PCR amplicons of *TNFSF9* (650 bp) were extracted with a gel-extraction kit and sequenced (Macrogen, Korea).

RNA isolation, and PCR amplification of *TNFSF9* cDNA
-----------------------------------------------------

Total RNA was isolated from HepG2 cells with Trizol RNA (Invitrogen, USA) and cDNA was synthesized with Accu-Power® CycleScript RT PreMix (Bionner, Korea) with 1 μg total RNA. PCR for *TNFSF9* cDNA was performed with Accu-Power® PCR PreMix (Bionner, Korea). The primers and PCR conditions for *TNFSF9* cDNA amplification are shown in [Table 1](#t1-molce-41-10-917){ref-type="table"}. Using the Primer-Blast program, the primers were designed to span an exon-intron boundary. The PCR products were separated by running on 1.2% agarose gels. PCR amplicons of *TNFSF9* cDNA (583 bp) were extracted with a gel-extraction kit, and the extracted DNAs were sequenced (Macrogen, Korea).

Real-Time PCR amplification of *TNFSF9* cDNA
--------------------------------------------

Real-time PCR analysis (MiniOpticon, Bio Rad, USA) was performed using PCR Master Mix (Takara SYBR® PreMix Ex Taq II) to quantify expression of *TNFSF9* mRNA (normalized to β-actin expression). Each sample was run in triplicate and threshold cycle (C~t~) values were averaged. Expression of the gene of interest was quantified as ΔC~t~ and normalized with the ΔC~t~ of β-actin. Amplification specificity was confirmed in each run by analyzing the melting temperature of the PCR product. Negative controls were run without cDNA templates. cDNA synthesis and quantitative PCR were performed in triplicate.

Isolation of *de novo* synthesized RNA, and PCR amplification of *TNFSF9* cDNA
------------------------------------------------------------------------------

Newly synthesized RNA transcripts were isolated from existing RNA with a Click-iT® Nascent RNA Capture Kit (Molecular Probes, Eugene, OR). HepG2 cells were incubated with 500 ng/ml LPS in the presence of 5-ethynyl uridine (EU), an analog of uridine, for 16 hrs. EU-labeled RNA from total RNA was biotinylated and then isolated by binding to streptavidin magnetic beads. The RNA bound to the beads was used as a template for cDNA synthesis. cDNA was synthesized by AccuPower® CycleScript RT PreMix (Bionner, Korea) using 1 μg total RNA. PCR for *TNFSF9* cDNA was done with AccuPower® PCR PreMix (Bionner, Korea). Primers and PCR conditions for *TNFSF9* cDNA amplification are shown in [Table 1](#t1-molce-41-10-917){ref-type="table"}. PCR products were separated by running on 1.2% agarose gels. PCR amplicons of *TNFSF9* cDNA (583 bp) were extracted with a gel-extraction kit and sequenced (Macrogen, Korea). For T7 endonuclease 1 activity assay, PCR products were annealed and incubated with T7E1 (NEB, Ipswich, MA) according to the instruction manual. The T7E1-treated PCR products were separated on 1.2% agarose gels and visualized under UV.

RESULTS AND DISCUSSION
======================

Site-directed mutagenesis of *TNFSF9* by CRISPR-Cas9
----------------------------------------------------

CRISPR-Cas9 was used with HepG2 cells to edit the 2^nd^ and 3^rd^ nucleotides of T[CT]{.ul} in *TNFSF9* to TAG, as described in Methods. TCT was shown by DNA sequencing to have been changed to T[AG]{.ul} in clones 9-1 and 14 ([Fig. 1](#f1-molce-41-10-917){ref-type="fig"}).

Re-editing of transcripts of edited genomic *TNFSF9*
----------------------------------------------------

To confirm that the edited T[AG]{.ul} in the *TNFSF9* gene of clone 9-1 and clone 14 was correctly transcribed to CUA, an amber stop codon, *TNFSF9* cDNA was amplified and sequenced from total RNA from clone 9-1 and 14. As shown in [Fig. 2](#f2-molce-41-10-917){ref-type="fig"}, the *TNFSF9* cDNA actually contained the wild-type triplet T[CT]{.ul}, indicating that the mutant triplet in *TNFSF9* was being re-edited to AGA during transcription. In addition, 1 or 2 bases just before T[CT]{.ul} were deleted in the *TNFSF9* transcript ([Fig. 2](#f2-molce-41-10-917){ref-type="fig"}). On the other hand, the *TNFSF9* transcript made from the clone 5 deletion mutant cells was itself mutant, as expected ([Fig. 2](#f2-molce-41-10-917){ref-type="fig"}). These data indicate that RNA editing occurs during transcription of *TNFSF9* in clone 9-1 and 14 cells.

Re-editing *de novo* synthesized transcripts from edited genomic *TNFSF9*
-------------------------------------------------------------------------

To examine if newly synthesized *TNFSF9* transcripts in clone 9-1 cells were edited, EU-labeled RNA was isolated from mutant cells treated with LPS and *TNFSF9* cDNA was amplified and sequenced. Incubation of HepG2 clone 9-1 cells with LPS for 16 h strongly up-regulated *TNFSF9* transcription ([Fig. 3A](#f3-molce-41-10-917){ref-type="fig"}) and sequencing of cDNA made from the EU-labeled transcripts again revealed re-editing of the transcripts to AGA. However, unlike in the case of the steady-state RNA, mixed peaks of *TNFSF9* cDNA were seen in the region of the triplet of interest ([Fig. 3B](#f3-molce-41-10-917){ref-type="fig"}), pointing to the presence of two indel *TNFSF9* cDNA PCR products in the region of the edited bases. To confirm the presence of these two indels, the *TNFSF9* cDNA PCR products were annealed and treated with endonuclease T7E1. As shown in [Fig. 4](#f4-molce-41-10-917){ref-type="fig"}, *TNFSF9* cDNA PCR products from EU-labeled transcripts were susceptible to T7E1 nuclease whereas those from total RNA were not, indicating that the *TNFSF9* cDNA PCR products from the EU-labeled transcripts were imperfectly matched. These data again indicate that the *TNFSF9 m*RNA transcribed from the edited genomic *TNFSF9* DNA was being re-edited in the process of transcription.

The data in this study clearly show that editing of genomic nucleotides by CRISPR-Cas9 can be followed by re-editing during transcription. It is likely that the sgRNA used in the initial editing is involved in this re-editing, acting as a template for re-editing the *TNFSF9* mRNA. Both the sgRNA plasmid and the Cas9 plasmid may have been retained in clone 9-1 and clone 14 even though it was continuously sub-cultured for a year. The plasmids may have been incorporated at random sites in the genome, and sgRNA transcript/Cas9 protein may be being continuously expressed. This interpretation is supported by our finding that the genomic DNA of clone 9-1 contained the sgRNA plasmid whereas that of wild type cells did not ([Fig. 5](#f5-molce-41-10-917){ref-type="fig"}). CRISPR-Cas9 has not been shown to be involved in any RNA (re-) editing but RNA editing has been reported in other CRISPR-Cas systems ([@b7-molce-41-10-917]; [@b17-molce-41-10-917]).

The mechanism(s) by which RNA re-editing occurs after DNA editing remains to be established. However, the findings of this study may act as a warning to researchers that undesirable target RNA re-editing can follow "correct" editing of target genes by CRISPR-Cas9.
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![DNA sequence of genomic *TNFSF9* gene edited by CRISPR-Cas9\
The *TNFSF9* genes in genomic DNAs from wild type and mutated HepG2 cells were amplified by PCR. The PCR products were isolated and sequenced as described in "Materials and Methods". Left panels are chromatograms of the genomic *TNFSF9* sequence. On the right are shown the DNA sequences around the region of the mutated triplet in the wildtype and mutant clones. This is one representative of five independent experiments.](molce-41-10-917f1){#f1-molce-41-10-917}

![cDNA sequence of mRNA transcribed from mutant genomic *TNFSF9*\
*TNFSF9* cDNA was synthesized and amplified by PCR from total RNA extracted from wild type and mutated HepG2 cells. The PCR products were isolated and sequenced as described in "Materials and Methods". Left panels are chromatograms of the *TNFSF9* cDNA sequences. On the right are shown the cDNA sequences around the region of the mutated triplet in the wild type and mutant clones. This is one representative of four independent experiments.](molce-41-10-917f2){#f2-molce-41-10-917}

![cDNA sequence of mRNA *de novo* transcribed from *TNFSF9* in HepG2 clone 9-1\
(A) HepG2 clone 9-1 cells were incubated with 500 ng/ml LPS for the indicated times. cDNA was synthesized from total RNA, and *TNFSF9* expression was quantified by real-time PCR as described in "Materials and Methods". (B) HepG2 cells were incubated with 500 ng/ml LPS in the presence of 5-ethynyl uridine (EU) for 16 hrs. EU-labeled RNA was isolated as described in "Materials and Methods". *TNFSF9* cDNA was amplified by PCR and the PCR products were isolated and sequenced. This experiment is representative of four independent experiments.](molce-41-10-917f3){#f3-molce-41-10-917}

![Heteroduplex formation by the cDNA of *de novo* transcripts of *TNFSF9* from HepG2 clone 9-1\
Total RNA and EU-labeled RNAs were isolated from clone 9-1 HepG2 cells. cDNA was synthesized and the *TNFSF9* cDNA was amplified by PCR as described in "Materials and Methods". The PCR products were annealed and incubated in the presence or absence of T7E1 endonuclease, and the products were fractionated on 1.2% agarose gels and visualized under UV. This is one representative of three independent experiments.](molce-41-10-917f4){#f4-molce-41-10-917}

![Detection of the sgRNA plasmid in HepG2 clone 9-1\
The sgRNA plasmid sequence was amplified by PCR from genomic DNA of wild type and clone 9-1 HepG2 cells, as described in "Materials and Methods". The PCR products were fractionated on a 2% agarose gel and visualized under UV. This is one representative of three independent experiments.](molce-41-10-917f5){#f5-molce-41-10-917}

###### 

PCR conditions

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Substrate          Primers (5′ to 3′)             PCR conditions                                                                                                                                                               Amplicon size
  ------------------ ------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  Genomic *TNFSF9*   For: GACATGCTCAGCTAAGCTAAGT\   Touchdown PCR: 95°C 3 min, 10 cycles of \[95°C /30 s, 72°C /30 s (−1°C per cycle), 72°C /45 s\], 25 cycles of \[95°C /30 s, 60°C /30 s, 72°C /45 s\], 72°C /5 min, 16°C /∞   650 bp
                     Rev: GAGGTCAGCAGCAGGGACC                                                                                                                                                                                    

  *TNFSF9* cDNA      For: GCCCAAAATGTTCTGCTGAT\     95°C /5 min, 35 cycles of \[95°C /20 s, 57°C /20 s, 72°C /45 s\], 72°C /5 min, 4°C /∞                                                                                        477 bp
                     Rev: TTATTCCGACCTCGGTGAAG                                                                                                                                                                                   

  SgRNA plasmid      For: GTGGAAAGGACGAAACACCG\     Touchdown PCR: 95°C 3 min, 10 cycles of \[95°C /30 s, 72°C /30 s (−1°C per cycle), 72°C /45 s\], 25 cycles of \[95°C /30 s, 60°C /30 s, 72°C /45 s\], 72°C /5 min, 16°C /∞   149 bp
                     Rev: ATATCTGGCCCGTACATC                                                                                                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
